Why the study?
Mean platelet volume could serve as a new biomarker for predicting or diagnosing ACS due to the crucial role of platelets in atherosclerosis.
Is mean platelet volume (MPV) higher in patients with acute coronary syndrome compared to those with noncardiac chest pain?
Is mean platelet volume (MPV) higher in patients with acute coronary syndrome compared to those with noncardiac chest pain?
Mean platelet volume is elevated in patients with acute coronary syndrome compared to noncardiac chest pain, suggesting its potential utility as a diagnostic biomarker.
Background: Acute coronary syndrome (ACS) is a group of symptoms associated with acute myocardial ischemia and is one of the major causes of morbidity and mortality across the world. Its primary etiology is atherosclerosis which is crucially dependent on platelets, and hence, mean platelet volume (MPV) could be a new biomarker for predicting or diagnosing ACS. Our study aims to measure the MPV in patients of ACS and compares it with patients of noncardiac chest pain to evaluate its usefulness as a new marker for ACS. Materials and Methods: A case–control study with 50 cases and 50 controls was carried out in SSG Hospital, Vadodara, over a period of 1 year (November 2016–November 2017). ACS patients were identified according to inclusion and exclusion criteria and their MPV was compared to that of noncardiac chest pain patients. Results: The cases had a higher MPV as compared to the control group, with both males and females being affected, but a stronger association was seen in case of males. Conclusions: Raised MPV has shown significant association with ACS and the test has reasonable sensitivity and specificity, which warrants larger scale studies to confirm its utility as a biomarker for ACS.
No takes yet. Share an insight, caveat, or question.
Dabhi et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: